Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 38394665

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2024 May 23
First author
van Outersterp I

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2024 May 23;143(21):2117-2118. doi: 10.1182/blood.2024024121.
    note
    Source null
    related pmid
    38780919
    relationship
    Comment in

Authors and identifiers

  1. name
    van Outersterp I
    type
    Author
  2. name
    Tasian SK
    type
    Author
  3. name
    Reichert CEJ
    type
    Author
  4. name
    Boeree A
    type
    Author
  5. name
    de Groot-Kruseman HA
    type
    Author
  6. name
    Escherich G
    type
    Author
  7. name
    Boer JM
    type
    Author
  8. name
    den Boer ML
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    van Outersterp I
    type
    Author
  2. name
    Tasian SK
    type
    Author
  3. name
    Reichert CEJ
    type
    Author
  4. name
    Boeree A
    type
    Author
  5. name
    de Groot-Kruseman HA
    type
    Author
  6. name
    Escherich G
    type
    Author
  7. name
    Boer JM
    type
    Author
  8. name
    den Boer ML
    type
    Author
bibliography ids
  1. nci-bib-a4f17dc5ff846c83037c5ed2
book metadata
content sha256
5139aaaa4589a43c1a471f5c5ce2db41516771e76aac7f021ce4caa72ad53a83
document type
citation
dois
  1. 10.1182/blood.2023023120
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:38394665
immutable id
pubmed:38394665@5139aaaa4589a43c1a471f5c5ce2db41516771e76aac7f021ce4caa72ad53a83
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
21
name
Blood
nlm unique id
7603509
pages
2178-2189
volume
143
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2024 May 23;143(21):2117-2118. doi: 10.1182/blood.2024024121.
    note
    Source null
    related pmid
    38780919
    relationship
    Comment in
outcomes validated
false
pmid
38394665
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
a65fa5f79a717780bc935870e893dcaf431e8be7470d6e7ba3188e407a6dee58
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2024 May 23
precision
day
year
2024
publication types
  1. Journal Article
  2. Research Support, Non-U.S. Gov't
  3. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38394665/
title
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.

Preserved source evidence · Independent clinical review pending · Not medical advice